Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

NCT03386721 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

256

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization, not due to any safety, efficacy, or quality issues.

Conditions

Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

Interventions

DRUG: simlukafusp alfa
DRUG: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
DRUG: Gemcitabine
DRUG: Vinorelbine

Sponsor

Hoffmann-La Roche